Bazarbek Demands Accountability for Billion-Tenge Losses in Kazakhstan's Pharma Sector

Kazakhstan's Pharmaceutical Sector Faces Scrutiny Amidst Billion-Tenge Losses NUR-SULTAN, Kazakhstan – A wave of criticism has hit Kazakhstan's pharmaceutical sector following a report by Majilis deputy Bakhytzhan Bazarbek. Bazarbek, in a recent public address, highlighted significant financial irregularities and inefficiencies within the system. The deputy's statement points towards substantial losses, estimated at over 14 billion tenge, due to what he describes as a flawed procurement and logistics model. "The audit revealed inflated prices for logistics services," Bazarbek stated, "and the lack of information on their own warehouses and transport led to a 62% increase in logistics costs in 2024." He further emphasized that these losses represent public funds and that those responsible must be held accountable. Bazarbek's sharp criticism is directed at both the Ministry of Health and the leadership of SK-Pharmacia, the state-owned pharmaceutical company. The deputy's announcement has sparked immediate calls for a thorough investigation into the matter. The public outcry reflects growing concerns over transparency and accountability within the country's healthcare system. Bazarbek's statement is expected to trigger further scrutiny and potential reforms aimed at improving efficiency and preventing future financial losses in the pharmaceutical sector.